Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin 750 mg for Acute Maxillary Sinusitis
NCT00236652Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2003
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of levofloxacin in Acute maxillary sinusitis (AMS), sponsored by Johnson & Johnson. Primary endpoint: Time to bacteriological eradication at Day 5. Started Nov 2003; status: completed.
02
Drugs
levofloxacin
03
Conditions
Acute maxillary sinusitis (AMS)
Beyond the preview
Go deeper on NCT00236652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236652.